Nurix Therapeutics (NRIX.US) Stock Price Surges! Its BTK degrading agent Bexobrutideg received positive test data

The Zhitong Finance App learned that the US biopharmaceutical company Nurix Therapeutics (NRIX.US) reported positive test data on Monday for its drug bexobrutideg in treating hematological cancers. Affected by this news, the stock closed up 18.68% to $21.47 on Monday.

According to reports, according to the latest data released by Nurix Therapeutics at the 2025 American Society of Hematology (ASH) annual meeting, the objective remission rate (ORR) (ORR) of patients treated with the novel oral Bruton's tyrosine kinase (BTK) degrading agent bexobrutideg (NX-5948) developed by the company in a phase 1a clinical trial treating R/R chronic lymphocytic leukemia (CLL) patients was 83%, with a median progression-free survival of 22.1 months. The duration of remission was 20.1 months. It is worth mentioning that these patients have previously received multiple treatments, including covalent and/or non-covalent BTK inhibitors. In the phase 1b patient cohort, early data showed an ORR of 83.3% of patients treated with Bexobrutideg at a dose of 600 mg. The company plans to choose a dose of 600 mg per day for the next step in development.

Furthermore, bexobrutideg also showed anticancer activity in a phase 1 clinical trial for patients with Walsh macroglobulinemia (WM) who had received multiple early treatments. Among the 28 WM patients whose efficacy could be assessed, ORR reached 75%. Paula O'Connor, the company's chief medical officer, said the data showed that relief was long-lasting and deepened as treatment time was extended, and the drug was well tolerated, which was consistent with previous disclosures. The company added that the drug's encouraging efficacy and good tolerability support its continued development.

Nurix Therapeutics focuses on the discovery, development and commercialization of oral small molecule therapies designed to regulate cellular protein levels as novel treatments for cancer and immune diseases. The company's R&D pipeline includes proteolytics targeting Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-cell lymphoma proto-oncogene-B (CBL-B, an E3 ligase that regulates T-cell activation). The drug candidate NX-2127 in its proteolytic product line is an orally available BTK degrading agent for the treatment of recurrent or refractory B-cell malignancies.

Data show that Bruton's tyrosine kinase (BTK) inhibitors are an important treatment option for various B-cell hematologic cancers. However, the emergence of BTK inhibitor resistance and the function of BTK that does not rely on kinase activity to mediate signal transmission have revealed the importance of using other means to target BTK protein function. Proteolytics targeting BTK provide an effective strategy for overcoming BTK inhibitor resistance by directly inducing BTK protein degradation by proteasomes.

It is worth mentioning that investment bank Needham reaffirmed its “buy” rating for Nurix Therapeutics on Monday, maintaining a target price of $26. The bank's analysts said that confidence in the company's market prospects remains unchanged. Last month, Truist gave Nurix Therapeutics a “buy” rating for the first time, with a target price of $30; BTIG reiterated its “buy” rating for Nurix Therapeutics, and the target price remained at $27. According to the 12-month target price given by 17 analysts, the analysts' average target price for Nurix Therapeutics is currently $27.18, the highest target price is $41, and the lowest target price is $15.